Vitiprints LLC & African distribution partner Uvukile Medical & Surgical Supplies (PTY) LTD. to play an essential role in stopping the spread of COVID-19 and its variants
NEW YORK–(BUSINESS WIRE)–Today, Vitiprints LLC announced that the company received an order from South Africa for 60 million Viracide™ Masks. The SAHPRA-approved, 4-PLY medical-grade Viracide™ Masks feature an antiviral and antibacterial coating that provides an additional tool in the battle against COVID-19, which will initially be available in South Africa and neighboring countries Lesotho and Swaziland. The order placed by Uvukile Medical and Surgical Supplies (PTY) LTD demonstrates the company’s essential role in stopping the spread of COVID-19 and its variants in Africa and around the globe.
“Viracide™ Masks will keep the people of Africa protected through this accessible and affordable medical device,” said Vitiprints co-founder John Gentile . “We believe that Viracide™ Masks are a critical health measure at stopping the spread of COVID-19 and the Omicron variant.”
A report this week from South African epidemiologist, Salim Abdool Karim announced that South Africa is expecting new cases to top over 10,000 cases by the end of this week per day. South Africa is the first country to join The Viracide™ Deactivation Nation global campaign—a call to action for countries to join together and deactivate COVID-19 by encouraging citizens to wear a Viracide™ Mask. Due to the overwhelming efficacy of its proprietary coating, the company is in the final phase of completing test requirements for US FDA 510K and CE certification by December 2021. Upon pre-market certification from the FDA and CE, Viracide™ Masks will be available to government agencies, medical groups, and consumers in the US and throughout Europe.
How Viracide™ Works:
Viracide™ masks protect users with a proprietary antiviral/antimicrobial coating that deactivates 99.97% of SARS-CoV-2 and 99% of Human Coronavirus (229E) under one minute of contact with the surface of the facemask. The disruptive technology used in Viracide™ Masks will help save lives by stopping the spread of COVID-19 and its variants. Mask-wearing is the single most effective public health measure at tackling COVID-19, reducing incidence by 53%, the first global study of its kind completed by BMJ, the highly regarded medical journal. Viracide™ masks can reduce the incidence to an even greater degree providing the wearer with both mask and enhanced antiviral.
“Having a true antiviral mask that can be sold at an affordable price is what South Africa and its neighbors need now,” as stated by the Director of Uvukile Medical and Surgical Supplies (PTY) LTD. “We believe the use of Viracide™ Masks will have an immediate impact on the spread of COVID-19 in Africa. We are working with SAHPRA and other Government and Humanitarian agencies across the continent to control COVID and save lives.” The UMS sales team is strategically placed with a national sales footprint in South Africa and various African countries, including but not limited to Namibia, Botswana and Zimbabwe. UMS leadership has been trusted and well known in the medical sector and other key industry sectors for over 20 years. With a network of trusted Global Partners, UMS Africa will pioneer the future expansion of the Viracide™ Masks and the expanding Viracide™ line of products.
• Viracide™ Masks can save the lives of Africans across the continent.
• Viracide™ Masks eliminate the risk of transmitting the virus—not only protecting the wearer from any airborne virus but also protecting anyone within the wearer’s proximity if they are positive for the virus, providing the ultimate two-way protection.
• SAHPRA-certified distribution to private hospitals, private clinics, medical professionals, and consumers
• Deactivates 99.97% of SARS-CoV-2 and 99% of Human Coronavirus (229E) under one minute of contact with the surface of the facemask
• Proprietary Viracide™ antimicrobial/antiviral cinnamon-scented coating deactivates specific viruses and bacteria in less than one minute of contact
• Viral Testing done at both FDA-approved US labs and China-based Wuhan Institute of Virology labs
• Testing found that 99% of a tested influenza strain [Influenza A Virus (H3N2)] is also fully deactivated within 30-minutes of contact with the surface of the facemask
• 4-ply construction with pleats, ear loops and multiple filtration layers protect against the transfer of microorganisms, body fluids and particulates
• Disposable surgical grade mask for personal or professional use
Viracide™ Masks are currently available for sale in specific international territories. Due to the overwhelming efficacy of its proprietary coating, the company is in the final phase of completing test requirements for US FDA 510K and CE certification by December 2021. Upon our pre-market certification from the FDA and CE, Viracide™ Masks will be available to government agencies, medical groups, and consumers in the US and throughout Europe.
Vitiprints LLC is dedicated to creating unique printed delivery system antiviral and antimicrobial formulations that protect both industry and home through masks, PPE, filtration, packaging, and more. Vitiprints also applies its advanced printing technology to uniquely manufacture food and non-food grade products by eliminating water & fillers in vitamins, beverages, milks, pharmaceuticals, personal care and cleaning products by dramatically reducing weight, size and cost. Vitiprints proprietary and patent-pending delivery system technology addresses environmental impact, logistics constraints, and profit margin pressure by printing fully functional, cost-effective products that reduce the need for plastic packaging or components. Its customizable print technology platform utilizes high speed, high-efficiency equipment for quick and cost-effective scaling of production capacity across many high-volume industries.